CA2834368C - Use of fk506 for the treatment of pulmonary arterial hypertension - Google Patents
Use of fk506 for the treatment of pulmonary arterial hypertension Download PDFInfo
- Publication number
- CA2834368C CA2834368C CA2834368A CA2834368A CA2834368C CA 2834368 C CA2834368 C CA 2834368C CA 2834368 A CA2834368 A CA 2834368A CA 2834368 A CA2834368 A CA 2834368A CA 2834368 C CA2834368 C CA 2834368C
- Authority
- CA
- Canada
- Prior art keywords
- mammal
- pulmonary arterial
- arterial hypertension
- dosage
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| US61/481,317 | 2011-05-02 | ||
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2834368A1 CA2834368A1 (en) | 2012-11-08 |
| CA2834368C true CA2834368C (en) | 2020-02-18 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2834368A Active CA2834368C (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (enExample) |
| EP (3) | EP2704711B1 (enExample) |
| JP (1) | JP6177765B2 (enExample) |
| AU (2) | AU2012250974B9 (enExample) |
| CA (1) | CA2834368C (enExample) |
| CY (1) | CY1123900T1 (enExample) |
| DK (2) | DK3821891T3 (enExample) |
| ES (2) | ES2856173T3 (enExample) |
| FI (1) | FI3821891T3 (enExample) |
| HR (1) | HRP20210245T1 (enExample) |
| HU (1) | HUE053229T2 (enExample) |
| LT (1) | LT2704711T (enExample) |
| PL (1) | PL2704711T3 (enExample) |
| PT (2) | PT3821891T (enExample) |
| RS (1) | RS61480B1 (enExample) |
| SI (1) | SI2704711T1 (enExample) |
| SM (1) | SMT202100085T1 (enExample) |
| WO (1) | WO2012151153A1 (enExample) |
| ZA (1) | ZA201307905B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2704711T3 (pl) | 2011-05-02 | 2021-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego |
| KR102569428B1 (ko) * | 2015-01-13 | 2023-08-21 | 비버스 인크. | 폐 고혈압을 위한 병용 요법 |
| EP3294294A4 (en) * | 2015-05-08 | 2019-01-02 | Vivus, Inc. | Compositions and methods for the treatment or prevention of pulmonary hypertension |
| CN108070566A (zh) * | 2015-08-05 | 2018-05-25 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| EP3624821A4 (en) | 2017-05-19 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION |
| US12440479B2 (en) | 2018-03-28 | 2025-10-14 | Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| CN101443004B (zh) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| FR2936060B1 (fr) | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| JP2012506434A (ja) * | 2008-10-22 | 2012-03-15 | サム アマー アンド カンパニー インコーポレーテッド | 肺動脈高血圧症の治療方法 |
| PL2704711T3 (pl) | 2011-05-02 | 2021-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego |
-
2012
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 SM SM20210085T patent/SMT202100085T1/it unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en not_active Ceased
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en not_active Withdrawn
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US12521379B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12521379B2 (en) | Use of FK506 for the treatment of pulmonary arterial hypertension | |
| Augustine et al. | Use of sirolimus in solid organ transplantation | |
| Stallone et al. | Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients | |
| Vincenti et al. | Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus | |
| JP7494277B2 (ja) | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 | |
| Reichenspurner | Overview of tacrolimus-based immunosuppression after heart or lung transplantation | |
| US20140113930A1 (en) | Therapeutic combination for cancer treatment | |
| EP4146202A1 (en) | Method of treating a patient infected with a coronavirus with nezulcitinib | |
| Valantine | Neoral use in the cardiac transplant recipient | |
| AU2010234360A1 (en) | Methods and compositions of PI-3 kinase inhibitors for treating fibrosis | |
| KR20050106038A (ko) | 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제 | |
| JP2018502126A (ja) | 肺高血圧症のための併用療法 | |
| Doyle et al. | RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis | |
| KR20250105629A (ko) | 유형 i 당뇨병에서의 만성 신장 질환의 치료 | |
| Mukherjee et al. | Immunosuppression in liver transplantation | |
| Lake | Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection | |
| Kane et al. | Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors | |
| Tönshoff et al. | Renal transplantation: Immunosuppression and managing allograft rejection | |
| WO2024243700A1 (en) | Methods for treating lupus nephritis with voclosporin | |
| ZAZA et al. | 18 mTOR Inhibitors: Sirolimus and | |
| Culos et al. | Immunosuppressive agents and monitoring in long‐term survivors | |
| Scholten et al. | Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170427 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 |